Stock comparison
Halozyme Therapeutics
Medtronic
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.18B
Sector
Healthcare
MDT
Medtronic
Market cap
$99.58B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | MDT | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 58D | HALO |
| Benjamin Graham | 83A | 63C | HALO |
| Philip Fisher | 65B | 50C | HALO |
| Peter Lynch | 53D | 55C | MDT |
| Joel Greenblatt | 40D | 39D | HALO |
| Charlie Munger | 80C | 51D | HALO |
| Terry Smith | 84A | 52D | HALO |
Side-by-side metrics
| Metric | HALO | MDT |
|---|---|---|
| Market cap | $8.18B | $99.58B |
| P/E (TTM) | 24.0x | 21.2x |
| EV/EBIT | 10.2x | 20.9x |
| ROIC (TTM) | 23.65% | 6.43% |
| Gross margin | 81.24% | 61.95% |
| Net margin | 23.13% | 13.0% |
| Revenue CAGR 5y | 33.23% | 2.73% |
| EPS CAGR 5y | -1.98% | 7.88% |
| Debt / Equity | 1.0x | 0.6x |
| Dividend yield | 0.0% | 3.73% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 2.73%+92%
- ROIC (TTM)23.65%vs 6.43%+73%
- EV/EBIT10.2xvs 20.9x+51%
- Net margin23.13%vs 13.0%+44%
MDT leads on
- EPS CAGR 5y7.88%vs -1.98%+125%
- Dividend yield3.73%vs 0.0%+100%
- Market cap$99.58Bvs $8.18B+92%
- Debt / Equity0.6xvs 1.0x+40%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.